Breaking
Sun Pharma agrees to supply atMFN pricing to U.S. medicaid programmes
The U.S. is the company’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue.
This story summarizes reporting from The Hindu. Read the original for full context. Wire items stay in our news sitemap for seven days. Editorial policy.
Read full story on The Hindu →
India — The Hindu

